Clinical Response to Infliximab after Secondary Failure with Adalimumab or Certolizumab Pegol in Crohn's Disease

被引：0
|
作者：
Trivella, Juan [1 ]
Yarur, Andres [1 ]
Moroney, James [1 ]
Deshpande, Amar [1 ]
Abreu, Maria [1 ]
Sussman, Daniel [1 ]
机构：
[1] Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2013年 / 108卷
关键词：
D O I：
10.14309/00000434-201310001-01855
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1855
引用
收藏
页码：S560 / S561
页数：2
相关论文
共 50 条
  • [31] Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review
    Da, Wei
    Zhu, Jinshui
    Wang, Long
    Lu, Yunmin
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2013, 25 (08) : 885 - 891
  • [32] Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
    Knyazev, O., V
    Kagramanova, A., V
    Lishchinskaya, A. A.
    Samsonova, N. G.
    Orlova, N., V
    Rogozina, V. A.
    Parfenov, A., I
    TERAPEVTICHESKII ARKHIV, 2018, 90 (06) : 74 - 80
  • [33] Certolizumab Pegol Plasma Concentration and Clinical Remission in Crohn's Disease
    Sandborn, William J.
    Hanauer, Stephen B.
    Pierre-Louis, Bosny
    Lichtenstein, Gary R.
    GASTROENTEROLOGY, 2012, 142 (05) : S563 - S563
  • [34] Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice
    Moon, W.
    Pestana, L.
    Becker, B.
    Loftus, E. V., Jr.
    Hanson, K. A.
    Bruining, D. H.
    Tremaine, W. J.
    Kane, S. V.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (04) : 428 - 440
  • [35] Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab
    Feagan, B. G.
    Sandborn, W. J.
    Wolf, D. C.
    Coteur, G.
    Purcaru, O.
    Brabant, Y.
    Rutgeerts, P. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (05) : 541 - 550
  • [36] Risk-benefit Assessment of Adalimumab and Certolizumab Pegol as Induction Treatment for Crohn's Disease
    Colombel, Jean-Frederic
    Panaccione, R.
    Robinson, Anne
    Thakkar, Roopal
    Huang, Bidan
    Pollack, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S466 - S466
  • [37] Antibodies to infliximab in patients with Crohn's disease do not cross-react with certolizumab pegol
    Vetterlein, O.
    Kopotsha, T. M.
    Nesbitt, A. M.
    Brown, D. T.
    Stephens, S.
    GUT, 2007, 56 : A116 - A116
  • [38] Azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn disease
    Marshall, John K.
    ANNALS OF INTERNAL MEDICINE, 2008, 148 (12)
  • [39] Response to the Letter to the Editor: "Response to Infliximab After Loss of Response to Adalimumab in Crohn's Disease"
    Casanova, Maria Jose
    Chaparro, Maria
    Gisbert, Javier P.
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (02) : E6 - E6
  • [40] Benefit of Infliximab Re-Introduction After Successive Failure of Infliximab and Adalimumab in Crohn's Disease
    Gagniere, Charlotte
    Beaugerie, Laurent
    Pariente, Benjamin
    Seksik, Philippe
    Amiot, Aurelien
    Abitbol, Vered
    Allez, Matthieu
    Cosnes, Jacques
    Sokol, Harry
    GASTROENTEROLOGY, 2014, 146 (05) : S456 - S456
12345